Skip to main content

Market Overview

Luminex Corporation and Bio-Techne Corporation Extend and Expand Partnership

Share:

Luminex Corporation (NASDAQ: LMNX) and Bio-Techne Corp (NASDAQ: TECH) today announced the signing of a new distribution and supply agreement through 2020. This agreement extends the relationship between the two companies for immunoassay development and commercialization of Bio-Techne biological content using the Luminex testing platform. Furthermore the agreement allows Bio-Techne to distribute Luminex multiplexing instrumentation, including the Luminex™ 200®, FLEXMAP 3D® and the MAGPIX® platforms in major markets worldwide.

Luminex logo
"We are very pleased to broaden our relationship with Bio-Techne, a leading global player in the research, diagnostics and clinical controls markets. We believe enabling Bio-Techne to develop assay content and distribute Luminex multiplexing instruments will aid our goal of providing laboratories of all sizes access to multiplexing solutions for a range of applications," said Todd Bennett, VP, Global Sales and Customer Operations, Luminex Corporation. "With its global scope, Bio-Techne is an ideal partner that can ensure our advanced multiplexing solutions reach the right scientists and researchers. This partnership will help accelerate science and improve the efficiency of disease-related research around the world."

"We have been a partner with Luminex for many years and given our strong market position in immunoassay applications, it is logical for Bio-Techne to continue to support our customers with complete customized workflow solutions, including instruments. This is consistent with the Company's strategic direction of providing full solutions in the Life Science research space, including both biological content and instruments," said Gerry Andros, VP of Sales for Bio-Techne Corporation.

Financial terms were not disclosed.

 

Related Articles (LMNX)

View Comments and Join the Discussion!

Posted-In: News Contracts Press Releases

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
SPAC
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com